Contineum Therapeutics, Inc.

CTNM · Nasdaq · SIC 2834: Pharmaceutical Preparations
36
SEC Filings

Business Summary

PART I . Overview We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. We target biological pathways associated with specific clinical impairments that we believe, once modulated, will demonstrably alter the course of disease. We focus on developing selective compounds targeting challenging molecular pathways and have built a portfolio of small molecule drug candidates. We believe our two clinical...

Next Earnings

Q2 FY2026 — expected 2026-09-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCTNMdiscussed_in_filing Cybersecurity
topic_mentionCTNMdiscussed_in_filing Trusted Computing
topic_mentionCTNMdiscussed_in_filing Blockchain & Crypto
topic_mentionCTNMdiscussed_in_filing Capital Expenditure
topic_mentionCTNMdiscussed_in_filing Regulation
topic_mentionCTNMdiscussed_in_filing Healthcare & Bio
topic_mentionCTNMdiscussed_in_filing Sovereign & Government
topic_mentionCTNMdiscussed_in_filing Cybersecurity
topic_mentionCTNMdiscussed_in_filing Trusted Computing
topic_mentionCTNMdiscussed_in_filing Blockchain & Crypto
topic_mentionCTNMdiscussed_in_filing Capital Expenditure
topic_mentionCTNMdiscussed_in_filing Regulation
topic_mentionCTNMdiscussed_in_filing Healthcare & Bio
topic_mentionCTNMdiscussed_in_filing Sovereign & Government
topic_mentionCTNMdiscussed_in_filing Cybersecurity
topic_mentionCTNMdiscussed_in_filing Trusted Computing
topic_mentionCTNMdiscussed_in_filing Blockchain & Crypto
topic_mentionCTNMdiscussed_in_filing Capital Expenditure
topic_mentionCTNMdiscussed_in_filing Regulation
topic_mentionCTNMdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-052025-12-310001628280-26-015165EDGAR96K words
2025-03-062024-12-310001437749-25-006458EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-10-302025-09-300001437749-25-032427EDGAR22K words
2025-08-052025-06-300001437749-25-024852EDGAR
2025-05-142025-03-310001437749-25-016835EDGAR
2024-11-062024-09-300001437749-24-033616EDGAR
2024-08-142024-06-300001437749-24-026680EDGAR
2024-05-162024-03-310001437749-24-017320EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-050001628280-26-015159EDGAR2K words
2026-01-260001437749-26-002072EDGAR
2025-12-150001437749-25-037842EDGAR
2025-12-110001437749-25-037547EDGAR
2025-11-200001437749-25-035860EDGAR
2025-10-300001437749-25-032422EDGAR
2025-09-180001437749-25-029349EDGAR
2025-08-050001437749-25-024849EDGAR
2025-06-260001437749-25-021343EDGAR
2025-05-140001437749-25-016877EDGAR

36 total filings indexed. 18 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001855175
TickerCTNM
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a2f47c7a7f7a511ddab8e7d9712c424059f074e77b85a1faff20057c90569d69
parent: 007b39487e02b456893a66ced3ac64d52d9b6328b8b3a7ee73d1ac34c2f30405
content hash: 954559b68142722799b40f8498599d421aaa31f3e1137036f5190604ba3f2f21
signed: 2026-04-13T04:44:32.279Z
sources: 8 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf